Image source: Getty Images.
It was great news all around for Cambrex Corporation (NYSE: CBM), manufacturer of small-molecule and generic active pharmaceutical ingredients, during the third quarter of 2016. The company announced solid results on both the top and bottom lines, and nudged its full-year guidance higher.